News

GT Medical Technologies Named as “Fierce 15” Company of 2019 by FierceMedTech

 

Company Recognized as One of the Most Promising MedTech Companies for Surgically Targeted Radiation Therapy Treating Patients With Brain Tumors

 

 

TEMPE, Ariz. — March 9, 2020 — GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that it has been named one of FierceMedTech’s 2019 Fierce 15, designating it as one of the most promising private MedTech companies in the industry. 

 

GT Medical Technologies was founded in 2017 by a group of brain tumor specialists with a purpose of improving the lives of patients with brain tumors.  The company’s goal is to elevate the standard of care for patients with brain tumors.  GammaTile® is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for patients with newly diagnosed malignant and recurrent intracranial neoplasms (brain tumors).  GammaTile came to market in 2019 and is currently available at top brain tumor treatment centers in the United States. 
 

“We are honored to be recognized by FierceMedTech and the medical technology community for our unwavering commitment to improving the lives of patients with brain tumors,” said Matthew Likens, president and CEO of GT Medical Technologies. “The burden of living with a brain tumor is significant and outcomes have improved little over the past 30 years for these patients. GammaTile Therapy is deployed during the last five minutes of a brain tumor resection procedure. It has been shown in clinical studies to significantly extend the time to tumor progression while removing the burden of radiation treatments from patients and their caregivers.”

 

“One of the true joys of covering this field is being able to talk with the people driving the next great medical advancements—technologies that may not just change a patient or parent’s life, but also the day-to-day work of clinicians, surgeons, researchers and developers themselves,” said Conor Hale, associate editor of FierceMedTech. “Potential breakthroughs such as these can ripple into new therapies, procedures and interventions, and ultimately more ways to heal more people.”

 

GammaTile received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors in July 2018. In January 2020, the FDA expanded GammaTile’s indication, allowing patients with newly diagnosed malignant brain tumors to receive the therapy. GammaTile Therapy is available to patients at more than a dozen leading health centers across the U.S. and is covered by Medicare and most private insurers.

 

The Fierce 15 celebrates the spirit of being “fierce”—championing innovation and creativity, even in the face of intense competition. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and competitive market position. This is FierceMedTech’s 8th annual Fierce 15 selection. This year’s full list can be viewed at: https://www.fiercebiotech.com/special-report/fiercemedtech-s-2019-fierce-15

 

About GT Medical Technologies, Inc.

Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with a purpose to prevent disease progression and improve quality of life for patients with brain tumors. GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors in July 2018 and has an established CMS code for Medicare reimbursement. Extensive clinical expertise informed the design of GammaTile Therapy, and deep medical device experience guides the company. The company is headquartered in Tempe, Arizona. For more information, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and on LinkedIn.

 

About GammaTile Therapy

GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors. Roughly the size of a postage stamp, GammaTile Therapy features a bioresorbable, conformable, 3D-collagen tile and uniform radiation source, Cesium-131, provided by Isoray, Inc. (NYSE: ISR). GammaTile Therapy is placed at the end of tumor removal surgery to immediately target residual tumor cells while limiting the impact of radiation on healthy brain tissue.

 

About FierceMedTech

FierceMedTech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical technology. More than 90,000 top industry professionals rely on FierceMedTech for an insider briefing on the day's top stories.

 

About Questex

Questex helps people live better and longer. Questex brings people together in the markets that help people live better: travel, hospitality and wellness; the industries that help people live longer: life science and healthcare; and the technologies that enable and fuel these new experiences. We live in the experience economy—connecting our ecosystem through live events, surrounded by data insights and digital communities. We deliver experience and real results. It happens here.

 

###

 

Media Contacts: 

Amy Cramer

Health+Commerce

Amy@healthandcommerce.com

650-391-3714

 

Rebecca Willumson

Questex, FierceMedTech

202-824-5050

rwillumson@questex.com

TREATMENT CONSIDERATIONS 

GammaTile Therapy is intended to deliver radiation therapy in patients with newly diagnosed malignant brain tumors and recurrent brain tumors. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). Serious side effects related to GammaTile Therapy are rare, and may include radiation brain changes including necrosis. GammaTile Therapy should not be used for patients with known history of hypersensitivity to bovine-derived materials. Possible complications can occur with any neurosurgical procedure, including cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation.

CONNECT WITH US
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube

©2020 GT Medical Technologies, Inc. I All rights reserved | Privacy Policy | Terms of Use

IMPROVING THE LIVES OF PATIENTS WITH BRAIN TUMORS